Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 May 1;49(5):454-456.
doi: 10.1097/RLU.0000000000005137. Epub 2024 Mar 6.

Extravasation After [ 177 Lu]Lu-HA-DOTATATE Therapy

Daphne M V de Vries-Huizing  1 , Zing J Cheung  1 , Jeroen J M A Hendrikx, Maarten L Donswijk  1 , Michelle W J Versleijen  1
Affiliations
Case Reports

Extravasation After [ 177 Lu]Lu-HA-DOTATATE Therapy

Daphne M V de Vries-Huizing et al. Clin Nucl Med. .

Abstract

Extravasation of the radiopharmaceutical during peptide receptor radionuclide therapy infusion is an unwanted infrequently reported event. We present the case of a 74-year old woman with a neuroendocrine tumor who was referred for peptide receptor radionuclide therapy. During intravenous infusion of 7.4 GBq [ 177 Lu]Lu-HA-DOTATATE in the upper right arm, extravasation of the radiopharmaceutical occurred through a displaced intravenous catheter. Planar scintigraphy showed pooling of radioactivity in the right upper arm. After 24 hours, the swelling in the arm was decreased; however, erythema was increased. One week later, symptoms had disappeared, and the patient did not experience any complications during follow-up of 11 months.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest and sources of funding: none declared.

Similar articles

See all similar articles

Cited by

References

    1. Huizing DMV, Peters SMB, Versleijen MWJ, et al. A head-to-head comparison between two commercial software packages for hybrid dosimetry after peptide receptor radionuclide therapy. EJNMMI Phys . 2020;7:36.
    1. Berry K, Kendrick J. Lutetium-177 radiopharmaceutical therapy extravasation lessons learned. Health Phys . 2022;123:160–164.
    1. van der Pol J, Vöö S, Bucerius J, et al. Consequences of radiopharmaceutical extravasation and therapeutic interventions: a systematic review. Eur J Nucl Med Mol Imaging . 2017;44:1234–1243.
    1. Arveschoug AK, Bekker AC, Iversen P, et al. Extravasation of [ 177 Lu]Lu-DOTATOC: case report and discussion. EJNMMI Res . 2020;10:68.
    1. Maucherat B, Varmenot N, Fleury V, et al. Effective management of 177 Lu-DOTA0-Tyr3-octreotate extravasation. Clin Nucl Med . 2021;46:144–145.

Publication types